Anti-Integrin alphaV beta3 Antibody, Non-Fucosylated (VPI-2690B) (CAT#: BioBet-1114ZP) Datasheet

Integrin α5β3

Integrin alphaV beta3

Integrin α5β3 consists of an α5 and a β3 heterodimer complex, which has been reported to bind to PECAM-1 (CD31), osteopontin, and vitronectin. Like α5β5 integrin, it has been found to be overexpressed in tumor cells and endothelial cells.

Integrin α5β3; Integrin alphaV beta3; ITGB3; ITGAV; ITGB3; BDPLT16; BDPLT2; CD61; GP3A; GPIIIa; GT

Plasma membrane

Diseases associated with ITGB3 include Glanzmann Thrombasthenia and Bleeding Disorder, Platelet-Type, 16.

Its related pathways are Monoamine Transport and RET signaling.

Integrin alpha-V/beta-3 (ITGAV: ITGB3) is cell actin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, Receptor for vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin, and vitronectin. Integrins alpha-IIb/ -3 and alpha-V/ -3 recognize R-G-D sequences in a variety of ligands. Integrin alpha-IIb/ -3 recognizes the H-H-L-G-G-G-A-K-Q-A-G-D-V sequence in the fibrinogen-chain. After activation, integrin alpha-IIb/ -3 causes platelet/platelet interaction by binding to soluble fibrinogen. This step leads to rapid platelet aggregation, physically blocking the ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (by similarity). ITGAV: ITGB3 binds to fractalkine (CX3CL1) and acts as its co-receptor in the fractalkine signaling pathway that cx3cr1 depends on. ITGAV: ITGB3 binds to NRG1 (via the EGF domain), and this combination is essential for NRG1-erbb signaling. ITGAV: ITGB3 binds to FGF1, and this combination is essential for FGF1 signaling. ITGAV: ITGB3 binds to FGF2, and this combination is essential for FGF2 signaling. ITGAV: ITGB3 binds to IGF1, and this combination is essential for IGF1 signaling. ITGAV: ITGB3 combines with IGF2, and this combination is essential for IGF2 signaling. ITGAV: ITGB3 binds to IL1B, and this combination is essential for IL1B signaling. ITGAV: ITGB3 and PLA2G2A bind through a site (site 2) that is different from the classical ligand binding site (site 1), thereby inducing a change in the conformation of the integrin and enhancing the binding of the ligand to site 1. ITGAV: ITGB3 acts as a receptor for fibrillin 1 (FBN1) and mediates r-g-d-dependent cell adhesion to FBN1. In the brain, it plays a role in synaptic transmission and plasticity. To participate in the regulation of serotonin neurotransmission, it is necessary to locate the serotonin receptor SLC6A4 to a specific area of ​​the synapse, and to re-uptake serotonin appropriately. By regulating the endocytosis of AMPAR containing gria2 to control excitatory synaptic strength, thereby affecting AMPAR abundance and composition (through similarity). ITGAV: ITGB3 acts as a receptor for CD40LG.

Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

VPI-2690B

Humanized

Human

VPI-2690B is a first-in-class subcutaneously (under the skin) administered monoclonal antibody with a unique mechanism of action. VPI-2690B binds to a very specific target in the kidney, the C-loop domain sequence within a cell's α5β3 receptor. To date, Vascular Pharmaceuticals has completed an ascending single/multiple dose Phase 1 study of VPI-2690B in healthy volunteers. The results showed that the drug is safe with significant levels of drug exposure and exhibited a consistent, predictable safety profile. A Phase 2 clinical trial is currently ongoing and is enrolling new patients.

Diabetic Nephropathy

Diabetic Nephropathy